发明名称 |
PHARMACEUTICAL COMBINATION COMPRISING A CIP2A SILENCING AGENT FOR USE IN THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER, PREFERABLY ONE WITH IMPAIRED P53 FUNCTION |
摘要 |
The invention is based on a finding that silencing CIP2A (KI-AA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject. |
申请公布号 |
US2014199415(A1) |
申请公布日期 |
2014.07.17 |
申请号 |
US201214343015 |
申请日期 |
2012.09.06 |
申请人 |
Westermarck Jukka;Cvrljevic Anna |
发明人 |
Westermarck Jukka;Cvrljevic Anna |
分类号 |
A61K31/7088;A61K45/06;A61K31/713 |
主分类号 |
A61K31/7088 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
Turku FI |